Lumida
/ACU
⌘K
Acme United Corp

Acme United Corp

ACU
$60.72USD-1.03%-0.63 today

MARKET CAP

232.8M

P/E (TTM)

25.8x

FWD P/E

22.5x

DAY RANGE

$60 – $61

52W RANGE

$36
$64

AI Summary

Stalk
TrimMedium

Given the dominant Stage 4 decline, medium-term bias remains bearish, recommending patience for a pullback into declining EMAs before engagement. Long-term trend remains intact bullish but non-actionable. Short-term lacks a clear edge, deferring execution until a bounce into resistance confirms timing. Overall posture is to await a more favorable entry for a directional trade aligned with the medium-term downtrend.

  • Q2 net sales jumped 16% YoY to $63 M, driving net income up 5% to $5.1 M
  • Gross margin improved to 42.6% in Q2, up 150 bps YoY on higher-margin first aid mix
  • Q1 net income fell 40% YoY to $0.985 M as tariff and material costs surged
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Acme United Corporation (NYSE: ACU) is a supplier in the consumer and industrial products market, notably specializing in first aid supplies and cutting tools. The company has been making substantial strides in enhancing its domestic manufacturing capabilities while adapting to the pressures created by fluctuating tariff environments. Its recent acquisitions, particularly of MyMedic, diversify its product offerings and position Acme United as a relevant player in both direct-to-consumer and retail channels. The business has a strong focus on innovation and operational efficiency, aiming to cut costs and enhance its market presence in essential products amid ongoing economic challenges.

Bull says

  • Q2 net sales jumped 16% YoY to $63 M, driving net income up 5% to $5.1 M
  • Gross margin improved to 42.6% in Q2, up 150 bps YoY on higher-margin first aid mix
  • MyMedic deal expands direct-to-consumer footprint and supports long-term growth
  • Generated ~$15 M free cash flow in Q2, reflecting strong operational liquidity
  • Strategic inventory and production shifts mitigate tariff cost impacts
  • Respectable earnings yield and dividend yield support total return potential

Bear says

  • Q1 net income fell 40% YoY to $0.985 M as tariff and material costs surged
  • U.S. gross margins declined about 100 bps ex-MyMedic amid high tariff pressures
  • Inflationary operating costs threaten to erode profitability in upcoming quarters
  • MyMedic integration poses execution risk and may weigh on short-term results
  • High leverage and low liquidity could strain balance sheet under stress
  • U.S. segment sales dipped 1%, highlighting sensitivity to consumer demand shifts

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-10-2026neutral

Transcript signals

Bull points

  • in the MedNap facility in Florida, Our revenues are up substantially, and they clearly are stressed. We're running two shifts, and we're working on new products and a lot of productivity improvements there.
  • We're also making major investments in documentation at MedNap and training in preparation for what we hope is some business in the future with the hospital market at MedNap.
  • The capital spending program continues to get more exciting because as we're generating we're generating more cash to reinvest in more and stronger automation.

Bear points

  • So when orders were canceled and programs were canceled in April and May, that directly impacted Westcott because those products that we would have shipped for sale for back to school were no longer going to be available, just canceled.
  • The market environment was particularly challenging due to tariffs.
  • While the second quarter was very challenging, I would like to thank our team for managing the tariff disruptions, working with our customers to meet their supply requirements, and executing well. They turned a challenge into an opportunity.
Read full transcript analysis ›